Identifying biomarkers for acute mesenteric ischemia
Biomarkers In Prediction of Acute Mesenteric Ischaemia: a Prospective Multicentre Study (BIPAMI Study)
This study is trying to find specific blood markers that can help doctors diagnose acute mesenteric ischemia and tell the difference between its more severe and less severe forms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Tartu Academic / other |
| Locations | 2 sites (Tartu and 1 other locations) |
| Trial ID | NCT06212921 on ClinicalTrials.gov |
What this trial studies
This study aims to identify specific combinations of biomarkers that can effectively diagnose acute mesenteric ischemia (AMI) and differentiate between its non-transmural and transmural forms. By analyzing sequential blood samples taken at various time points after symptom onset, the research seeks to establish reliable diagnostic criteria for different sub-types and severities of AMI. The approach focuses on enhancing the accuracy of AMI diagnosis, which is critical for timely intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who are being considered for further diagnostics of mesenteric ischemia.
Not a fit: Patients under 18 years old or those with chronic mesenteric ischemia without an acute event may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for acute mesenteric ischemia, allowing for quicker and more effective treatment.
How similar studies have performed: While the specific approach of this study may be novel, previous research has shown promise in using biomarkers for diagnosing various ischemic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Initial decision in favour of further diagnostics of mesenteric ischaemia Exclusion Criteria: * Age \<18 years * Consent declined by patient or next of kin (delayed consent) * Chronic mesenteric ischaemia without an acute event * Immediate decision for withdrawal of further diagnostics and active treatment * Referral from another hospital with already established diagnosis of AMI * AMI diagnosed at surgery without previously having been considered
Where this trial is running
Tartu and 1 other locations
- Tartu University Hospital — Tartu, Estonia (Recruiting)
- Lucerne Cantonal Hospital — Lucerne, Switzerland (Recruiting)
Study contacts
- Study coordinator: Annika Reintam Blaser, PhD
- Email: annika.reintam.blaser@ut.ee
- Phone: +3725142281
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.